文献速递儿科与产科急症呼吸衰竭与机械通气

儿童移植受者COVID-19的急诊科评估

Emergency department evaluation of transplanted children with COVID-19.
PubMed 文献 · Am J Emerg Med · 2023-12-12
一句话结论儿童实体器官移植和造血干细胞移植受者感染SARS-CoV-2后临床表现以发热为主,总体病程和结局良好,无死亡。

这项在西班牙马德里3家三级医院开展的多中心回顾性观察描述性研究,纳入2020年3月至2022年12月急诊科就诊的0-18岁实体器官移植(SOT)或造血干细胞移植(HSCT)且SARS-CoV-2检测阳性的连续患儿。共31例,HSCT 16例(51.6%)、SOT 15例(48.3%),移植至COVID-19中位时间1.2年(IQR 0.5-5.1)。仅1例无症状,最常见症状为发热(76.7%);12例胸片中8例(66.6%)异常;13例(41.9%)住院,无死亡。不同移植类型或免疫抑制状态间临床表现、淋巴细胞减少和影像学表现无显著差异。

要点

  • 31例儿童移植受者中仅1例无症状,发热为最常见就诊症状(76.7%)。
  • 12例接受胸片检查者中8例(66.6%)见异常,但不同移植类型或免疫抑制状态间影像学无显著差异。
  • 13例(41.9%)住院,无死亡,作者认为SOT和HSCT儿童COVID-19总体病程和结局良好。
  • 移植至COVID-19中位时间1.2年(IQR 0.5-5.1),SOT以肝、肾移植各4例(12.9%)最多。

适用人群与场景

  • 2020年3月至2022年12月在西班牙马德里3家三级医院儿科急诊就诊的0-18岁实体器官移植(SOT)或造血干细胞移植(HSCT)患者。
  • 纳入标准:鼻咽样本SARS-CoV-2实时聚合酶链反应或抗原检测阳性;连续纳入。

研究设计与关键结果

  • 多中心回顾性观察描述性研究,纳入31例儿童移植受者,其中HSCT 16例(51.6%)、SOT 15例(48.3%)。
  • SOT队列包括肝移植4例(12.9%)、肾移植4例(12.9%)、心脏移植3例(9.7%)、多器官移植3例(9.7%)、肺移植1例(3.2%)。
  • 移植至COVID-19中位时间1.2年(IQR 0.5-5.1)。
  • 31例中仅1例无症状,最常见就诊症状为发热(76.7%)。
  • 12例接受胸片检查,其中8例(66.6%)见异常。
  • 不同移植类型或免疫抑制状态间临床表现、淋巴细胞减少和影像学表现无显著差异。
  • 13例(41.9%)住院,无患者死亡。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察描述性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,本研究中SOT和HSCT儿童COVID-19的临床病程和结局总体良好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Children usually have an asymptomatic or mild course of SARS-CoV-2 infection, studies in immunocompromised patients have shown a different evolution. The aim of this study was to describe the clinical, laboratory, and radiologic manifestations of pediatric solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) patients testing positive for SARS-CoV-2.

METHODS: A multicenter retrospective, observational descriptive study was conducted in 3 tertiary hospitals in Madrid (Spain) between March 2020 and December 2022. Consecutive patients aged 0-18 attending the corresponding pediatric emergency departments with a positive result in the real-time polymerase chain reaction test or antigenic test to detect SARS-CoV-2 in the nasopharyngeal sample were included.

RESULTS: A total of 31 children were included in the study. Sixteen (51.6%) were patients with HSCT and 15 (48.3) were patients with SOT. The median time from transplantation to COVID-19 was 1.2 years (IQR:0.5-5.1). The SOT cohort included liver (n = 4, 12.9%), kidney (n = 4, 12.9%), heart (n = 3, 9.7%), multivisceral (n = 3, 9.7%), and lung (n = 1, 3.2%). Of the 31 patients, only one was asymptomatic. The most common symptom on presentation was fever (76.7%). Abnormalities were seen on chest X-ray in 8 (66.6%) of the 12 patients. There was no significant difference in clinical manifestations, lymphopenia and radiological findings regardless of the type of transplantation or immunosuppression status. Thirteen patients (41.9%) were hospitalized. There were no patient deaths.

CONCLUSIONS: In our study, we found that the clinical course and outcome of SOT and HSCT pediatric patients with COVID-19 were generally favorable.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Barreiro Pérez S, Molina Gutiérrez MÁ, Antoñanzas Bernar V, et al. Emergency department evaluation of transplanted children with COVID-19. Am J Emerg Med. 2023. PMID: 38118387. doi:10.1016/j.ajem.2023.12.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。